Can patients with urticaria receive the 9-valent HPV vaccine?

Generally speaking, receiving the 9-valent cervical cancer vaccine refers to being vaccinated with the 9-valent human papillomavirus (HPV) vaccine. Whether patients with urticaria can receive this vaccine depends on their specific condition. If the patient's condition is stable, vaccination is usually acceptable; however, if the condition is in an acute flare-up phase, vaccination is not recommended. Detailed analysis is as follows:

If a patient with urticaria has a stable condition, serious adverse reactions due to individual differences are unlikely, and therefore, receiving the 9-valent HPV vaccine is generally safe. Tolerable adverse reactions include the absence of symptoms such as fever, skin itching, or other significant discomfort.

However, if a patient with urticaria is in the acute phase of an outbreak, the skin barrier function may be compromised, making the patient potentially more susceptible to certain components in the vaccine, which might trigger or worsen symptoms of urticaria. Additionally, during an outbreak, patients may have an allergic constitution, and vaccination might exacerbate symptoms such as rash and itching, or even lead to severe complications like laryngeal edema and difficulty breathing. Therefore, vaccination with the 9-valent HPV vaccine is not advised during this period.

To ensure safety and effectiveness, patients with urticaria should consider receiving the 9-valent HPV vaccine only after their condition has stabilized or fully resolved. Before vaccination, individuals should thoroughly inform their physician about their health status and allergy history so that the doctor can assess whether vaccination is appropriate.